Heart Failure Toolkit for PCPs (Revised May 2025)

Contents

| Introduction Letter |
|---|
| Heart Failure (HF) Care Guidelines |
| Heart Failure (HF) - Provider One Pager5 |
| Care Guidelines: Heart Failure (HF)7 |
| Medication Guidelines: Heart Failure (HF)9 |
| Heart Failure (HF) Action Plan11 |
| Heart Failure (HF) Comorbid Conditions12 |
| Palliative Care in Heart Failure (HF)14 |
| Heart Failure Coding and Clinical Documentation15 |
| Clinical Documentation: Heart Failure and Pre-Heart Failure16 |
| Clinical Documentation: ESHF/Heart Assistive Devices17 |
| Heart Failure (HF) Coding and Clinical Documentation19 |
| Coding Decision Tree |
| Heart Failure Coding |
| Direct Test Ordering |
| Direct Test Ordering |
| |
| Cardiac Solutions Referral Form29 |
| Cardiac Solutions Referral Form29 CVAM Referral Form |
| |
| CVAM Referral Form |
| CVAM Referral Form.30Tri-City Cardiology Referral Form.31Care Management and Support Resources32Patient Heart Failure (HF) Action Plan.33Care Management Referral Form36Palliative Care Providers37Home Care Providers38 |
| CVAM Referral Form30Tri-City Cardiology Referral Form31Care Management and Support Resources32Patient Heart Failure (HF) Action Plan33Care Management Referral Form36Palliative Care Providers37Home Care Providers38Additional Resources39 |

Introduction Letter

Dear Providers:

Banner Plans & Networks (BPN) providers continue to make strides in impacting the quality of care for our members, and as part of the ongoing work our Cardiology Clinical Strategy Committee has devised clinical best practices and a toolkit for PCPs to improve outcomes for patients with heart failure.

Within BPN's Medicare & Medicare Advantage populations, around 18% of members have a heart failure diagnosis, which is above the national average. Additionally, heart failure is often mis- or under-diagnosed, leading to members not getting appropriate care early in their disease state¹.

BPN's heart failure patients have an average annual medical spend about \$17,400 more than those without diagnosed heart failure. Hospital readmission and emergency department visits are twice as likely to happen with this patient population and they are 5 times more likely to have an inpatient hospital stay.

To help us better manage patients with heart failure, we have included these tools:

- NEW Heart Failure Provider One Pager
- Heart Failure Best Practices
- Heart Failure Medication Guidelines (Updated)
- NEW Heart Failure Action Plan
- NEW Heart Failure Co-Morbid Conditions
- NEW Palliative Care and Heart Failure
- Heart Failure Coding and Clinical Documentation Resource (Updated)
- NEW Direct Test Ordering Guide
- Heart Failure Patient Resources (Updated)

In addition to the resources provided in the toolkit, this video series from American Journal of Managed Care, offers helpful insights for treatment of heart failure in primary care.

https://www.ajmc.com/view/identifying-key-risk-factors-for-heart-failure

Thank you for taking the time to review these materials. We hope these resources assist you in your practice. Thank you for your ongoing work to help BPN make health care easier, so life can be better. Please consult your Care Transformation Consultant with questions.

Sincerely,

Dr. Ed Clarke, MD

VP, CMO Banner Plans & Networks

Heart Failure (HF) Care Guidelines

Heart Failure (HF) - Provider One Pager

Primary care providers (PCPs) play a crucial role play in early identification, treatment, and ongoing care of patients with heart failure.

Early Identification

Many individuals have multiple risk factors, significantly increasing their risk of developing heart failure.¹ Screening high-risk individuals allows for early diagnosis and treatment, preventing further damage to the heart and minimizing complications, leading to better long-term outcomes.

Risk Factors

- Coronary Artery Disease (CAD)
- History of Myocardial Infarction (MI)
- Hypertension (HTN)
- Diabetes
- Age 65 years or older
- Obesity
- Sedentary lifestyle
- Smoking/tobacco use

Alcohol or drug abuse

Diagnostic Tools

No single test definitively diagnoses heart failure; a comprehensive evaluation is necessary using both physical examinations and diagnostic tests.

- ECHO (Echocardiography) to evaluate ejection fraction and structural abnormalities of the heart.
- BNP (B-type natriuretic peptide) or NT-proBNP to check for markers of heart failure.
- Chest X-ray to check for pulmonary congestion or pleural effusion.
- ECG (Electrocardiogram) to assess for arrhythmias or signs of ischemia.
- Exercise Stress Test to measure the heart's function and blood flow under pressure.

Heart Failure Management by PCPs

PCPs are equipped to manage and treat heart failure without a specialist cardiology consult.

Direct Test Ordering

Diagnostic tools such as ECHOs and exercise stress tests are available for **Direct Test Ordering** from one of our preferred cardiology providers.

Provide patient education and a Heart Failure Action Plan

| Heart Failure Action Plan | | |
|---|--|--|
| Educate patients and caregivers about their condition and treatment plan. Emphasis the importance of medication adherence and daily self-monitoring. | Ensure patients recognize early signs of worsening heart failure (e.g., sudden weight gain, increased shortness of breath, swelling) that indicate when to seek medical attention. | |

Recommend Lifestyle Modifications

- ✓ Recommend a low-sodium, heart-healthy diet and fluid restriction in patients with fluid overload
- Promote regular aerobic exercise as tolerated
- Encourage weight management
- ✓ Urge smoking cessation and alcohol reduction

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Provider One Pager

Signs & Symptoms

- Dyspnea and/or orthopnea
- Edema in feet, ankles, legs or abdomen
- Sudden weight gain
- Frequent coughing or wheezing
- Unexplained fatigue
- Lack of appetite or nausea
- Confusion or impaired thinking •
- Rapid or irregular heartbeat
- New onset chest pain

Guideline-Directed Medical Therapy (GDMT)

Once diagnosis is confirmed, accurate **HF classification and staging** helps guide therapy and prognosis. Follow **GDMT** which is considered the cornerstone of managing heart failure, and has been shown to improve cardiac function, quality of life, and functional status, and to decrease risks of hospitalization and mortality.²

Primary Heart Failure Pharmacological Therapy

Optimize medications such as ACE inhibitors, ARBs, beta-blockers, MRAs, and SGLT2 inhibitors based on HF classification and comorbid conditions. In patients with chronic symptomatic HFrEF NYHA II or III who tolerate an ACEi or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality.

Management to Slow Disease Progression

| Monitoring and Follow-up | | |
|--|---|--|
| • Frequent Visits | Schedule Annual Wellness Visits (AWV) and ensure regular follow-up to assess symptom progression, adjust medications, and monitor for side effects. | |
| • Regular Monitoring | Keep track of weight, blood pressure, and renal function (especially in patients on diuretics and ACE inhibitors). | |
| • Heart Rate & Rhythm | Monitor for arrhythmias, especially atrial fibrillation, which can exacerbate symptoms. | |
| Manage Comorbid Conditions | Managing comorbid conditions in heart failure is a critical component of care, as comorbidities can significantly affect the progression of the disease, its symptoms, and overall prognosis. | |

Proper Coding

Providers should document the etiology, type, and acuity of heart failure whenever possible. Also include any causative factors, such as alcohol, diabetes, HTN, ischemia, CKD, rheumatic, etc.

| Type of He | eart Failure | Acuity/Status of Condition |
|--|--|---|
| Systolic, Diastolic or | Congestive | Acute (decompensated) |
| Combination | Left or right side | Chronic (compensated) |
| Reduced or preserved | Pre-heart failure | Acute on chronic |
| ejection fraction | End-stage | Historical condition only |

Indications for Cardiology Co-Management

Heart failure patients should be referred to a cardiologist when newly diagnosed, experiencing severe (NYHA Class III-IV) symptoms, showing rapid deterioration despite treatment, having unclear etiology, requiring advanced therapies/devices, or having recurrent hospitalizations.


Additional Resources

| Support Teams & Services | | | |
|-------------------------------|----------------------|------------------------------------|--|
| Care Management | Mobile Providers | Palliative Care | |
| Services include: | Services include: | Services include: | |
| Community resources | Home NP/PCP visits | Patient centered treatment goals & | |
| Disease & lifestyle education | Mobile Labs/X-ray | condition management | |
| Post discharge assistance | Same-day urgent care | Coordination with PCP office | |
| CM Referral Form | Home Care Providers | Palliative Care Providers | |

Care Guidelines: Heart Failure (HF)

Heart failure is one of the most common causes of heart-related illness and death in the United States. In fact, it is one of the most common reasons people aged 65 and older go into the hospital. Therapy should be individualized based on comorbid conditions, overall clinical status, tolerance to, and possible contraindications to guideline-directed medical therapy (GDMT).

HF Classification (1)



Adapted from the American Academy of Family Physicians

than 40% is heart failure with improved ejection fraction

Non-Pharmacologic Heart Failure Management

| Regular Clinical Re-Evaluation & Care | Frequency is dependent on the severity of HF symptoms and comorbid conditions | |
|--|--|--|
| | Early post-discharge provider follow-up (within 7 days) Annual Wellness Visit (AWV) | |
| Lifestyle Modification | • Diet | |
| | • Exercise | |
| | Weight loss | |
| | Smoking cessation | |
| | • Alcohol use counselling (<2 standard drinks/day for men; <1 | |
| | standard drink/day for women) | |
| | Substance use disorder (SUD) management | |
| Comprehensive Self-Care Education | Include education on HF Action Plan | |
| Psychosocial Care: | Screen for depression, social isolation, frailty, low health | |
| Address potential barriers to self-care | literacy, and SUD | |
| | Screen for Social Determinants of Health (SDOH) and refer to appropriate resource | |
| Coordinated Care: | To include: | |
| Multi-disciplinary care team approach | • PCP | |
| ······ | Consider Cardiology co-management. | |
| | • Care Management team (RN, SW, Pharmacy, RD, etc.) | |
| Exercise Training/Cardiac Rehabilitation | | |
| Timely Palliative or Hospice Care | Patients with advanced HF refractory to optimum GDMT | |
| Discussions | Recommend palliative care early for symptom management | |
| Complete Vaccination Evaluation | • Influenza, Covid-19, Pneumococcal, RSV, etc. | |
| | • | |

LVEF **NYHA Functional** Stage Management Recommendations Classification А NA NA Control comorbidities Consider SGLT-2i in diabetics >40% В NA Control comorbidities Consider SGLT-2i in diabetics <40% Class I Control comorbidities ACEi (preferred) or ARB Consider Heart failure-specific beta blockers Consider SGLT-2i in diabetics >50% (HFpEF) Class I C and D Control comorbidities Consider SGLT-2i in diabetics Class II-IV Control comorbidities Loop diuretics, if congested Consider SGLT-2i Consider (based on lower end LVEFs and comorbidity): ARNi (preferred) or ACEi or ARB Heart failure-specific beta blockers MRA 41%-49% (HFmrEF) Class I Control comorbidities Class II-IV Control comorbidities Loop diuretics, if congested SGLT-2i Consider: ARNi (preferred) or ACEi or ARB Heart failure-specific beta blockers MRA • <40% (HFrEF)</p> Control comorbidities Class I ACEi or ARBs Heart failure-specific beta blockers Class II-III Control comorbidities ARNi (preferred) or ACEi or ARB Heart failure-specific beta blockers MRA Loop diuretics, if congested SGLT-2i Class IV Control comorbidities Heart failure-specific beta blockers Loop diuretics, if congested MRA SGLT-2i Improved from <40% Continue GDMT based on lowest previous EF even All classes (HFimpEF) in asymptomatic patients to prevent relapse.

Primary Guideline-Directed Medical Therapy (GDMT) (1)(2)

Indications For Cardiology Co-Management Referral⁽³⁾

- Persistent NYHA Functional class III-IV symptoms while on optimum GDMT
- Systolic BP <90 mmHg or symptomatic hypotension
- Creatinine <u>>1.8</u> or BUN <u>>43</u> MG/DL
- Presence of the following history:
 - Atrial Fibrillation
 - Ventricular Arrhythmias
 - Repetitive ICD shocks
- \geq 2 ED visits or hospitalizations for worsening HF in prior 12 months
- Persistently reduced LVEF ≤35% despite ≥3 months on optimum GDMT (for consideration of device therapy if no previous use of ICD or CRT)

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Page | 8

Medication Guidelines: Heart Failure (HF)

Primary Heart Failure Pharmacological Therapy

Select one: ARNi, ACEi, or ARB.

Allow a 36-hour washout period when switching from an ACEi to ARNi to minimize potential for angioedema. No washout period is necessary for patients previously on an ARB.

| llse / Indication | Drug Options | Starting Dose | Target Dose |
|--|---|---|---|
| In HFrEF and NYHA II-III, | Sacubitril/ | 24/26mg- | 97/103mg |
| the use of ARNi is | valsartan | 49/51mg BID | BID |
| morbidity and mortality. In | | | |
| | | | |
| uncontrolled BP despite | | | |
| therapy, ARNi may be | | | |
| | | | |
| those with lower end of the | | | |
| Used as second line therapy | Captopril | 6.25mg TID | 50mg TID |
| | Enalapril | 2.5mg BID | 10-20mg BID |
| ACEi is beneficial in reducing | Fosinopril | 5-10mg QDay | 40mg QDay |
| morbiaity and mortality. | Lisinopril | 2.5-5mg QDay | 20-40mg QDay |
| | Perindopril | 2mg QDay | 8-16mg QDay |
| | Quinapril | 5mg BID | 20mg BID |
| | Ramipril | 1.25-2.5mg QDay | 10mg QDay |
| | Trandolapril | 1mg QDay | 4g QDay |
| In patients with previous or current symptoms of chronic | Candesartan | 4-8mg QDay | 32mg QDay |
| HFrEF who are intolerant to ACEi because of cough or | Losartan | 25-50mg QDay | 50-150mg QDay |
| angloedema and when the use of ARNi is not feasible, | Valsartan | 20-40mg QDay | 160mg BID |
| the use of ARB is | | | |
| morbidity and mortality. | | | |
| | • | , | 10mg QDay |
| HFpEF if comorbidity | | _ | 25-50mg BID |
| | | / | 80mg QDay |
| lower end of LVEF range. The use of one of the three | Metoprolol (CR/XL) | 12.5-25mg QDay | 200mg QDay |
| HF beta blockers is | | | |
| mortality and | | | |
| hospitalizations. | | | |
| | the use of ARNi is recommended to reduce morbidity and mortality. In select HFpEF patients with persistent symptoms and uncontrolled BP despite SGLT2i and MRA optimal therapy, ARNi may be considered to reduce hospitalizations especially in those with lower end of the spectrum LVEF. Used as second line therapy if ARNi is not tolerated or is not affordable. The use of ACEi is beneficial in reducing morbidity and mortality. In patients with previous or current symptoms of chronic HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARNi is not feasible, the use of ARB is recommended to reduce morbidity and mortality. Indicated in HFrEF and HFmrEF. Considered in HFpEF if comorbidity warrants. Can also be considered in HFpEF at lower end of LVEF range. The use of one of the three HF beta blockers is recommended to reduce mortality and | In HFrEF and NYHA II-III, the use of ARNi is recommended to reduce morbidity and mortality. In select HFpEF patients with persistent symptoms and uncontrolled BP despite SGLT2i and MRA optimal therapy, ARNi may be considered to reduce hospitalizations especially in those with lower end of the spectrum LVEF. Used as second line therapy if ARNi is not tolerated or is not affordable. The use of ACEi is beneficial in reducing morbidity and mortality. In patients with previous or current symptoms of chronic HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARNi is not feasible, the use of ARB is recommended to reduce morbidity and mortality. Indicated in HFrEF and HFmFF. Considered in HFpEF if comorbidity warrants. Can also be considered in HFpEF at lower end of LVEF range. The use of one of the three HF beta blockers is recommended to reduce mortality and | In HFrEF and NYHA II-III, the use of ARNi is recommended to reduce morbidity and mortality. In select HFpEF patients with persistent symptoms and uncontrolled BP despite SGLT2i and MRA optimal thespitalizations especially in those with lower end of the spectrum LVEF.Sacubitril/ valsartan24/26mg- 49/51mg BIDUsed as second line therapy if ARNi is not tolerated or is not affordable. The use of ACEi is beneficial in reducing morbidity and mortality.Captopril Enalapril Fosinopril6.25mg TID 2.5mg BIDIn patients with previous or current symptoms of chronic HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARN is not feasible, HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARN is not feasible, HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARN is not feasible, HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARN is not feasible, HFrEF who are intolerant to ACEi because of cough or angioedema and when the use of ARN is not freasible, Indicated in HFrEF and HFrEF if comorbidity warrants. Can also be considered in HFrEF and HFrEF if comorbidity warrants. Can also be considered in HFPEF at lower end of LVEF range. The use of one of the three HF beta blockers is recommended to reduce morbidity andBisoprolol Carvedilol CR Metoprolol (CR/XL)1.25mg QDay 12.5-25mg QDay |

| Drug Class | Use/Indication | Drug Options | Starting Dose | Target Dose |
|--|--|---|-----------------------------|---------------------------|
| SGLT2-inhibitor | SGLT2-inhibitors are recommended to reduce hospitalization for HF and cardiovascular mortality irrespective of the presence of type 2 diabetes. Caution initiating with impaired renal function. Avoid use in Type 1 diabetics and in diabetics with history of, or predisposition to, DKAs. | Dapagliflozin Empagliflozin | 10mg QDay 10mg QDay | 10mg QDay 10mg QDay |
| Mineralocorticoid Receptor Antagonist (MRA) | MRA can be used in both HFrEF and HFpEF with evidence of weaker efficacy in HFpEF than in HFrEF. MRA can be used if eGFR >30mL/min/1.73m ² and serum potassium is <5.0 mEq/L. Careful monitoring of potassium, renal function, and diuretic dosing should be performed at initiation and closely monitored according to clinical status (approximately 1 week, then 4 weeks, then every 6 months afterward) to minimize risk of hyperkalemia and renal insufficiency. | Spironolactone Eplerenone | 12.5-25mg QDay 25mg QDay | 25-50mg QDay 50mg QDay |
| Vasodilators | Recommended in African- American patients in NYHA III-IV | Hydralazine/ isosorbide dinitrate | 37.5mg/20mg TID | 75mg/40mg TID |

Medications to Avoid with Heart Failure (not-all inclusive)

| Mediention Class | Detionale | Alternatives to consider |
|---|---|--|
| Medication Class | Rationale | Alternatives to consider |
| Thiazolidinediones (in | Increases risk of HF | Metformin (in stable heart failure) |
| HFrEF) ⁽¹⁻³⁾ | decompensation/hospitalizations | or SGLT2 inhibitor if appropriate |
| (i.e. Pioglitazone) | | |
| Non-dihydropyridine | Higher risk of recurrent HF | Amlodipine |
| calcium channel blockers | symptoms | |
| (in HFrEF) ⁽¹⁾⁽⁴⁻⁶⁾ | | |
| (i.e. Diltiazem) | | |
| NSAIDs (1)(7-8) | Increases morbidity and mortality | Acetaminophen |
| (i.e. Ibuprofen/Naprosyn) | | |
| DDP-4 (Saxagliptin and Alogliptin only) ⁽¹⁾⁽⁹⁾ | Concern for increased risk of HF hospitalizations | Metformin (in stable heart failure) or SGLT2 inhibitor if appropriate |

ACEi/ARBs should not be used with a history of angioedema/other allergic reactions. Caution utilizing ARNIs with hypotension, advanced kidney disease, or hyperkalemia.⁽¹⁾ These situations may require ARNI temporary discontinuation, lower dosing, or switching between classes. True contraindications to goal directed medication therapy are rare, such as advanced degree atrioventricular block and the use of beta blockers in the absence of pacemakers, or cardiogenic shock that has not resolved.

Tip Sheet

Heart Failure (HF) Action Plan

A heart failure action plan is crucial for managing and improving outcomes for patients with heart failure and should be based on the type of heart failure, severity of the condition, as well as the patient's age and comorbidities. Taking a proactive approach is a vital to:

- Preventing hospitalizations and readmissions
- Slowing disease progression
- Improving quality of life

Heart Failure Action Plan/Self Check Plan

Every patient with heart failure should have a personalized **Heart Failure Action Plan** or **Self Check Plan** and should be encouraged to keep a written copy where it is easy to locate. This plan can help empower patients and their caregivers to manage their condition by:

- Daily monitoring and medication adherence
- Recognizing early warning signs of worsening symptoms
- Understanding when to contact their provider or seek emergency care

Refer to the Heart Failure Action Plan Zones Chart below for corresponding symptoms:

| | No changes needed, continue: | |
|-------------|--|---|
| Green Zone | Daily weight checks | Monitor symptoms |
| (Stable) | Eat low salt/sodium food | Balance activity and rest |
| | ✓ Take medications as directed | Follow-up visits with providers |
| Yellow Zone | Contact doctor or health care team | |
| (Caution) | Symptoms may indicate that an adjustment in lifestyle or medications is needed | |
| Red Zone | See a doctor or heath care professional right away | |
| (Emergency) | Call 911 or go to ER immediately | |

Heart Failure Action Plan Zones

| Green Zone: Stable Continue Self-Management | | |
|---|------------------|--|
| Symptoms are under control | Weight is stable | |
| No new or worsening shortness of breath No chest pain | | |
| No swalling in fact, and loss land an abdaman | | |

- No swelling in feet, ankles, legs or abdomen
- Physical activity is normal

| Heart Failure Warning Zones | | |
|--|---|--|
| Yellow Zone: CAUTION Contact Health Care Team | Red Zone: EMERGENCY Seek Immediate Medical Care! | |
| Chronic dry, hacking cough Worsening shortness of breath with activity or while lying flat Increased swelling in legs, ankles, feet or abdomen Sudden weight gain of >2-3lbs in 24-hour period (or 5 lbs. within a week) Increased fatigue/ tiredness | Frequent dry, hacking cough Struggling to breath/ unrelieved shortness of breath even at rest Severe swelling in legs, ankles, feet or abdomen New or worsening dizziness or confusion New onset chest pain Loss of appetite | |

Heart Failure (HF) Comorbid Conditions

Managing comorbid conditions in heart failure (HF) is a critical component of care, as comorbidities can significantly affect the progression of the disease, its symptoms, and overall prognosis. The role of primary care providers (PCPs) is essential in managing these comorbidities alongside heart failure treatment.

| Condition and Impact on Heart Failure | Management | | |
|--|---|--|--|
| Chronic Obstructive Pulmonary Disease (COPD) Often coexists with HF, | Medications: Continue COPD management with bronchodilators (beta- agonists, anticholinergics) and corticosteroids as indicated. Be cautious with beta-blockers as they can exacerbate bronchospasm, though they are often necessary for HF. | | |
| particularly in older adults, and managing both conditions is | Oxygen therapy: For patients with hypoxia or advanced COPD. | | |
| essential. | Pulmonary rehabilitation: Encourage participation to improve functional capacity. | | |
| Hypertension Is a major risk factor for the | Medications: ACE inhibitors, ARBs, beta-blockers, and calcium channel blockers are used to control blood pressure. | | |
| development and progression of HF, particularly HF with | Lifestyle modifications: Encourage weight management, low-sodium diet, exercise, and alcohol reduction. | | |
| preserved ejection fraction (HFpEF). | Regular monitoring: Regular BP checks to adjust medications and ensure target levels (generally <130/80 mm Hg) are achieved. | | |
| Diabetes Mellitus | Glycemic control: Target A1c of 7% or lower, but individualized. | | |
| Increases the risk of HF, worsens prognosis, and can complicate management due to medication interactions and the | Medications: Metformin is often first-line unless contraindicated (e.g., renal insufficiency). SGLT2 inhibitors (like empagliflozin or dapagliflozin) are recommended for HF with reduced ejection fraction (HFrEF), as they improve outcomes. | | |
| effects of hyperglycemia on heart function. | Lifestyle : Encourage diet modification, regular exercise, and weight management. | | |
| Chronic Kidney Disease (CKD) | Medications : Adjust doses of HF medications (e.g., ACE inhibitors, ARBs, diuretics) based on kidney function. Use SGLT2 inhibitors carefully, as they are beneficial in both HF and diabetes but require renal monitoring. | | |
| Often coexists with HF and can worsen both conditions, leading | Monitor kidney function : Regular monitoring of creatinine and GFR. Avoid nephrotoxic agents where possible. | | |
| t"cardiorenal syndrome." | Fluid management: Cautious use of diuretics to prevent volume overload without worsening kidney function. | | |
| | Rate control : Beta-blockers, calcium channel blockers (verapamil or diltiazem), or digoxin. | | |
| Atrial Fibrillation Is common in patients with HF and can worsen symptoms and increase the risk of stroke. | Rhythm control : Antiarrhythmic drugs (e.g., amiodarone, flecainide) may be considered. | | |
| | Anticoagulation : Use anticoagulation for stroke prevention based on CHA2DS2-VASc score (commonly apixaban, rivaroxaban, or warfarin). | | |
| | Close monitoring : Regular ECGs to assess rhythm and adjust therapy as needed. | | |

| Condition and Impact on Heart Failure | Management | |
|---|---|--|
| Anemia | Screening: Regular hemoglobin and hematocrit measurements. | |
| Can worsen HF symptoms by | Iron supplementation: For iron deficiency anemia (oral or IV iron). | |
| decreasing oxygen delivery to tissues. | Erythropoiesis-stimulating agents: May be considered in severe anemia, especially in CKD. | |
| Hyperlipidemia Is a risk factor for the development of coronary artery | Statins: Use statins for cardiovascular disease prevention unless contraindicated (e.g., in advanced HF with very low ejection fraction, where the benefit may be less clear). | |
| disease, which can contribute to heart failure. | Lifestyle: Diet modification (low-fat, heart-healthy diet), exercise, and weight loss. | |
| Depression and Anxiety | Screening: Use screening tools such as the PHQ-9 for depression and GAD-7 for anxiety. | |
| Are common in HF patients and can negatively affect quality of | Treatment: Antidepressants (SSRIs/SNRIs) or referral to counseling and psychotherapy (cognitive-behavioral therapy) if necessary. | |
| life and adherence to treatment. | Support: Encourage participation in support groups or other mental health resources. | |
| | Screening: Ask about symptoms of sleep apnea (e.g., loud snoring, daytime sleepiness). | |
| Obstructive Sleep Apnea (OSA) Is common in HF and can worsen both HF symptoms and outcomes. | Treatment: CPAP (continuous positive airway pressure) therapy for patients diagnosed with OSA or Inspire therapy, a minimally invasive, FDA-approved treatment for OSA that uses an implanted device to keep the airway open during sleep. | |
| outcomes. | Weight loss: Encourage weight management, as it can improve sleep apnea severity. | |
| Obesity Contributes to the development | Lifestyle interventions: Diet modifications (low-sodium, Mediterranean diet), weight loss programs, and regular exercise (such as walking, swimming). | |
| and worsening of HF, particularly HFpEF, and can | Psychosocial support: Refer to weight management programs and counselors if needed. | |
| complicate medication adherence. | Consider bariatric surgery: In severe cases of obesity, if other methods fail. | |

Palliative Care in Heart Failure (HF)

Palliative care is team based supportive care and plays a crucial role in improving the quality of life for individuals living with heart failure (HF), particularly those with advanced or end-stage heart disease. It is important to remember that palliative care is appropriate at any stage of the disease journey, not just at the end of life and can work alongside other treatments aimed at improving heart function or managing acute symptoms.

Palliative care is NOT synonymous with hospice care

While heart failure is a chronic and progressive condition, palliative care focuses on symptom management, emotional support for patients and their caregivers, and helping guide decision-making at different stages of the disease.

| Components | Approach and Interventions |
|--|--|
| Multidisciplinary Team Based-Care & Coordination of Care | Team Based-Care: Palliative care providers collaborate with primary care, cardiologists, social workers, dietitians, spiritual care providers, and other specialists to ensure seamless communication amongst the care teams to provide coordinated, holistic care. Care Coordination: Help patients and families navigate complex healthcare needs and systems, ensuring continuity of care, and preventing unnecessary hospitalizations. |
| Symptom Management | Dyspnea: One of the most common and distressing symptoms in advanced heart failure. Palliative care can provide medications like opioids to ease breathlessness or use non-pharmacological interventions like supplemental oxygen or positioning. Fatigue: A hallmark of heart failure and can significantly affect daily functioning. Palliative care can provide energy conservation techniques and help in planning daily activities, balancing rest and activity. Medications like antidepressants may also be considered if fatigue is related to depression. Pain/Discomfort: Some patients with advanced disease may experience discomfort, either from the heart failure itself or comorbid conditions and can be managed with analgesics, including opioids in appropriate doses. Edema: Medications, such as diuretics, can help reduce fluid buildup. Palliative care providers can also assist with physical therapies and techniques to relieve swelling and reduce discomfort. Depression and Anxiety: It is common for heart failure patients to experience mental health struggles. Counseling, cognitive behavioral therapy, and antidepressant or anti-anxiety medications can be helpful. |
| Psychosocial Support & Family Support | Emotional Support: Addresses the psychological impact of advanced heart failure, including grief, fear, and loss of independence. Caregiver Support: The physical and emotional toll on caregivers can be significant. Offering support, counseling, respite care, and educational resources can help families navigate the challenges of a serious illness. |
| Advance Care Planning | • Goals of Care: Palliative care teams help facilitate conversations with patients and families about the prognosis and disease progression. This process allows patients to express their wishes regarding treatment goals, advance directives, code status and end of life care. |
| Transition to Hospice Care | • End of Life Care: For patients with end-stage heart failure, where prognosis is limited, palliative care can help transition to hospice services. This provides a focus on comfort care during the final stages of life, aiming for dignity, pain control, and support for both the patient and family. |

Palliative Care Providers List

Heart Failure Coding and Clinical Documentation

Clinical Documentation: Heart Failure and Pre-Heart Failure

| THE DIAGNOSIS | Heart Failure and Pre-Heart Failure | | | | |
|---|---|--|--|--|--|
| COMMON | Heart failure, unspecified (Pre-HF) – I50.9 | | | | |
| COMMON CONDITIONS | Left ventricular failure – I50.1 | | | | |
| INCLUDED IN HCC | Chronic systolic (congestive) heart failure (HFrEF) – I50.22 | | | | |
| GROUP 226 | Chronic diastolic (congestive) heart failure (HFpEF) – I50.32 | | | | |
| RAF Score = 0.360 | Chronic right heart failure – I50.812 | | | | |
| KEY CODING or DOCUMENTATION TIPS | There is a causal relationship between heart failure and hypertension. If your patient has heart failure and it is NOT linked to a declining cardiovascular status due to hypertension, then your note needs to explain that the two are not linked. | | | | |
| | Essential or benign hypertension (I10) is NOT the most appropriate diagnosis for a patient with heart failure, and the coder should update the diagnosis or query the provider. | | | | |
| MEAT the | Assessment and Plan example: | | | | |
| DOCUMENTATION | Heart failure, unspecified (I50.9) | | | | |
| | Hypertensive heart disease with heart failure (I11.0) | | | | |
| M = Monitor E = Evaluate A = Assess/Address | Mr. X presents today for his wellness exam. He reports that he saw Dr. Cardio regarding his heart failure last month and no new medications were added. His blood pressure today was 142/84 and he denies any SOB or chest pain. He has 2+ pitting edema in bilat legs. Heart sounds normal, no gallop or murmur. Reviewed lab results taken last month after his cardiology appointment with him and answered all questions regarding his heart failure. | | | | |
| T = Treat | M – Signs and symptoms, such as chest pain, SOB, edema. | | | | |
| | E – Test results or vital signs, such as BNP or renal panels. | | | | |
| | A – Order tests or patient discussion, such as echocardiogram. | | | | |
| | T – Medications, therapy, or other modalities, Entresto or cardiac rehab. | | | | |
| IMPACT on QUALITY - HEDIS MEASURE | Heart failure diagnoses (I50.x) are considered advanced illness diagnoses. When added to a claim twice in the current or prior year meets the advanced illness criteria. | | | | |
| | Frailty or advanced illness, ESRD, and/or palliative care diagnosis codes may provide a denominator exclusion. | | | | |
| | CMS quality metrics regarding heart failure: | | | | |
| | CMS 135 – HF: ACE or ARB or ARNI Therapy for LV systolic dysfunction CMS 144 – HF: Beta-blocker therapy for LV systolic dysfunction | | | | |
| | Pey: 12/2024 | | | | |

Rev: 12/2024

Clinical Documentation: ESHF/Heart Assistive Devices

| THE DIAGNOSIS | End Stage Heart Failure and Heart Assistive Devices | | |
|---|---|--|--|
| COMMON CONDITIONS INCLUDED IN HCC GROUP 222/223 RAF Score = 2.505 | HCC 222: End stage heart failure (ESHF) – I50.84 HCC 223: Presence of heart assist device – Z95.811 Presence of fully implantable artificial heart – Z95.812 | | |
| | Consider ESHF as the patient's diagnosis if the patient has evidence of | | |
| KEY CODING or DOCUMENTATION TIPS | Stage D, Class III/IV heart failure. ESHF disrupts the patient's ADLs and severe symptoms persist despite being on the optimal medical therapy. Expect the patient to have the following findings: (1) EF ≤ 25%, (2) Significant (echo) structural findings that indicate worsening heart function, (3) Frequent hospitalizations for HF issues, (4) Two signs and symptoms "at rest" – SOB, chest pain, dyspnea, persistent cough, inability to lie flat, etc., (5) two or more heart failure medications to support heart function and symptoms of HF. Provider documentation of the clinical evaluation and judgement is the gold standard of this diagnosis. You may see this condition suspected based on a prospective review of the patient's chart. The concurrent coder may query a provider if there are any questions regarding this diagnosis. | | |
| MEAT the | Assessment and Plan example: | | |
| DOCUMENTATION | End-stage heart failure (I50.84) Hypertensive heart disease with heart failure (I11.0) | | |
| M = Monitor E = Evaluate A = Assess/Address | Mr. P presents today for his AWV. The patient reports that he has no energy and can't sleep in his bed anymore. He sleeps in his recliner. He can't put his socks on anymore, and he gets SOB walking to the bathroom with is walker. He saw Dr. Cardio regarding his heart failure last month and they reviewed his recent Echo. His EF is 22%. He is on metoprolol and lisinopril. His blood pressure today was 112/65. He has 3+ pitting edema in bilat legs. Heart sounds muffled and S4 gallop noted. Rales bilaterally. | | |
| T = Treat | M - Signs and symptoms, such as chest pain, SOB, edema, at rest. E - Test results or vital signs, such as EF and BNP A - Order tests or patient discussion, such as echocardiogram. T - Medications, therapy, or other modalities, Entresto or cardiac rehab. | | |

| IMPACT on QUALITY - HEDIS MEASURE | ESHF and Heart Assistive Devices diagnoses are considered advanced illness. When added to a claim twice in the current or prior year meets the advanced illness criteria and will remove a patient from the denominator for many quality metrics. |
|--------------------------------------|---|
| | Frailty or advanced illness, ESHF, ESRD, and/or palliative care diagnosis codes may provide a denominator exclusion. |
| | CMS quality metrics regarding heart failure: CMS 135 - HF: ACE or ARB or ARNI Therapy for LV systolic dysfunction CMS 144 - HF: Beta-blocker therapy for LV systolic dysfunction |
| | Remember that I10 – essential or benign hypertension is NOT an appropriate diagnosis for someone with advanced heart disease. Make sure to use I11.0, I13.0, or I13.2 for your patient with ESHF and/or an assistive heart device. This will be the most appropriate code for the patient, and it removes them from the high blood pressure quality metric. |
| | CMS 165 – Controlling High Blood Pressure |

Heart Failure (HF) Coding and Clinical Documentation

Providers should document the etiology, type, and acuity of heart failure (HF) whenever possible:

Type of Heart Failure

- Systolic, Diastolic or Combination Systolic and Diastolic
- Reduced or preserved ejection fraction (HFrEF. HFimpEF, or HFpEF)
- Congestive
- Left or right side
- Pre-heart failure
- End-stage

Acuity/Status of the Condition

- Acute (decompensated)
- Chronic (compensated)
- Acute on chronic
- Historical condition only

It is good practice to include the status of the ejection fraction (EF). For example, a patient with HF and an EF \leq 40 is considered to have heart failure with reduced ejection fraction or HFrEF (I50.22). Also include any causative factors, such as alcohol, diabetes, hypertension, ischemia, kidney disease, rheumatic, and so on. Remember, heart failure is not always "congestive," and selecting a diagnosis to the highest level of specificity (such as left, right, HFrEF, HFpEF, PreHF, etc.) is highly recommended.

Terms such as *diastolic dysfunction* or *restrictive ventricular disease* are not synonymous with heart failure and requires provider linkage to heart failure to select the appropriate code. The Coder should query for the provider for the specific condition(s).

Coding Guidelines - Heart Failure (HF) - I50.XX

Remember to first code the following diagnoses, if applicable:

Code First

- heart failure complicating abortion or ectopic or molar pregnancy (000-007, 008.8)
- heart failure due to hypertension (I11.0)
- heart failure due to hypertension with chronic kidney disease (I13.-)
- heart failure following surgery (I97.13-)
- obstetric surgery and procedures (075.4)
- rheumatic heart failure (I09.81)

Excludes 2 Note: The following codes are allowed to be coded with the HF codes, if applicable and documented by the clinician:

- cardiac arrest (I46.-)
- neonatal cardiac failure (P29.0)

Important to remember

When seeing your patient for a post hospitalization follow-up for heart failure, add the appropriate diagnosis code and documentation for the patient's health status at the time of the visit. Do not utilize the inpatient admit and discharge diagnoses.

Hierarchical Condition Categories for Heart Failure

When the V28 CMS HCC risk adjustment model was introduced, it was noted that the heart failure and heart disease diagnoses that were once lumped into HCC 85 (V24 model) are now broken out into five distinct groups. Two additional groups were added for diagnoses that were part of HCC 186 and are part of the heart hierarchy, which focus on heart transplants and heart assistive devices. Breaking these diagnoses out into separate groups allows for more precise and accurate risk adjustment factor (RAF) values to be assigned to these distinctly different diagnostic groups, which vary significantly by complexity. This further allows for more appropriate allocation of funds for the proper care of patients who fall into these groups that require increased frequency of visits and/or tests and monitoring. The HCC groups, description and RAF values are listed below.

| V28 HCC Group | Description | V28 RAF |
|------------------|---|---------|
| HCC221 | Heart Transplant Status/Complications | 1.053 |
| HCC222 | End-Stage Heart Failure | 2.505 |
| HCC223 | Heart Failure with Heart Assist Device/Artificial Heart | 2.505 |
| HCC224 | Acute on Chronic Heart Failure | 0.360 |
| HCC225 | Acute Heart Failure (Excludes Acute on Chronic) | 0.360 |
| HCC226 | Heart Failure, Except End-Stage and Acute | 0.360 |
| HCC227 | Cardiomyopathy/Myocarditis | 0.189 |

Other Specialized Heart Failure Diagnoses

Pre-Heart Failure (PreHF) – I50.9

- Stage B heart failure per the American College of Cardiology and the American Heart Association.
- Persons without current or previous symptoms of heart failure <u>AND</u> either structural heart disease, abnormal cardiac function (such as filling pressures), or other risk factors (such as abnormal BPN when no signs of CKD or myocarditis).
 - Examples of structural heart disease
 - Left ventricular hypertrophy (LVH)
 - Valvular heart disease
 - Chamber dilation (atrial and ventricular)
 - Cardiomyopathy

Note: heart failure stages A, B, C, and D are based on the American College of Cardiology and American Heart Association stages for heart failure, which complement, and should not be confused with, the New York Heart Association Classification of Heart Failure, into Class I, Class II, Class III, and Class IV

stage A Z91.89 stage B (*see also* Failure, heart, by type as diastolic of systolic) I50.9

stage C (*see also* Failure, heart, by type as diastolic of systolic) I50.9

stage D (see also Failure, heart, by type as diastolic of systolic, chronic) I50.84

Page 259 of the AAPC 2024 ICD-10-CM Expert coding book.

• End Stage Heart Failure (ESHF) – I50.84

- Stage D heart failure.
- Advance stage of heart failure, in which the heart has become too weak to effectively pump blood throughout the body.

• End Stage Heart Failure (ESHF) – I50.84 (continued)

- \circ The patient begins to have more signs and symptoms of HF at rest.
- BPN recommended clinical signs for classifying ESHF:
 - Echo ≤ 25% AND
 - Structural findings on echo (Ex. LVH, LAD, DD, etc.) <u>AND</u>
 - Two HF medications <u>AND</u>
 - Signs and Symptoms usually more than one that significantly interfere with performing one's ADLs.
 - SOB at rest
 - Dyspnea at rest
 - Persistent cough
 - CP at rest
 - Pitting edema grade 3 or 4
 - Extreme fatigue/weakness
 - Inability to lie flat (when sleeping)
 - Cardiac assist devices
 - Frequent hospitalization for HF

• Hypertensive Heart Disease

Essential hypertension is the most common ICD-10 diagnosis used across the country. It is also known that hypertension, especially uncontrolled hypertension, is a precursor for many other health conditions, such as heart failure (HF) and chronic kidney disease (CKD). Providers may not be aware that the AMA assumes a causal relationship between hypertension and the previously mentioned diseases. So much so, that for CKD *not to* "*be linked*" to hypertension, the <u>provider is required</u> to document that the patient's declining kidney health is due to another reason, like polycystic kidney disease.

CMS 165, the Controlling High Blood Pressure (C-HBP) quality metric, looks for two things when determining who falls into the denominator for the C-HBP quality measure:

- A diagnosis of essential hypertension (I10) during the previous year or first 6 months of the current measurement year.
- A qualifying adult outpatient encounter.

If your patient has hypertension, heart failure, and/or CKD, you will want to select the diagnosis code most appropriate for them.

There are two key elements that *must be included* when using the hypertensive heart and/or chronic kidney disease diagnoses:

- You must include the corresponding HF, CKD, or HF & CKD diagnoses in the same visit encounter:
 - Unspecified systolic (congestive) heart failure I50.20
 - CKD Stage 3a N18.31
 - Chronic systolic (congestive) heart failure (HFrEF) I50.22
 - CKD Stage 3b N18.32
 - Chronic diastolic (congestive) heart failure (HFpEF)– I50.32
 - CKD Stage 4 N18.4
 - Heart failure, unspecified I50.9
 - CKD Stage 5 N18.5

• You must include the appropriate documentation to support your medical decision making for this diagnosis. Remember the MEAT mnemonic may help!

Clinical Documentation Examples:

Below are two examples of appropriate documentation for two different patients who have heart failure.

- <u>A/P</u>:
 - Mr. X is a 68-year-old male patient seeing his PCP for his annual physical.
 - Hypertensive heart disease with systolic heart failure (I11.0, I50.20)
 - BP 152/88 today. On valsartan with moderate control. Review of labs show potassium 3.8. +1 pitting edema in bilateral ankles/feet. Has scheduled follow-up with cardiologist next week. No changes to meds.

Putting it all together:

- 65-year-old male with a hx of MI 5 years ago, smoking x 30 years and quitting 5 years ago is here for worsening LE edema (painful) and 7 lb. weight gain. He does have a hx of well controlled diabetes and "mild kidney disease". He is taking medication for his blood pressure. At his last office visit he was ordered an Echocardiogram with his results ready for review.
 - Ht: 5'8", Weight: 260 lbs, T: 98.6, RR: 16, HR: 94, BP 146/92, BMI 39.5
 - PMHX: HTN, Obesity, Diabetes, Hx MI
 - SocHX: 30 ppy hx quit 5 years ago, School teacher.
 - Meds: Lisinopril 20 mg, Metformin 1000mg bid
 - Labs: GFR: 27 (last week) and 29 (3 mon ago) HGBA1C 7.3
 - Echo: EF 35%, Left atrial enlargement
 - GEN: Well-appearing, obese
 - CV: RRR, S1, S2
 - PULM: Decreased breath sounds
 - EXT: +2 pitting edema bilaterally to shins. Varicose veins bilaterally


A/P:

- HFrEF I50.22 (0.360) Start sacubitril/valsartan 49/51 bid and metoprolol 25mg ER once daily. Discussed pressure socks/stockings. May consider spironolactone at next visit.
- Hypertensive heart and kidney disease I13.0 (No RAF) Start sacubitril/valsartan 49/51. Start metoprolol 25 mg ER once daily, stop lisinopril.
- 3. CKD Stage 4 N18.4 (0.514) Avoid NSAIDs, encourage weight loss. Keep bp controlled. Monitor q 3 months.
- 4. Diabetes with CKD –E11.22 (0.166)– Start Dapagalifozin 5 mg once daily. Stop Metformin (low GFR)
- 5. Obesity, class 3– E66.813 (0.186) Obesity complicated by diabetes and heart failure. *Referral* to dietitian. BMI 39.5 with comorbid condition of CHF

Remember to always tell the best patient story when selecting the most appropriate diagnosis and completing your documentation!

Coding Tip Sheet

Coding Decision Tree



Adapted from ©AAPC All Rights Reserved

Coding Tip Sheet

Heart Failure Coding

| Heart Failure Diagnosis | ICD-10-CM Diagnosis Code | HEDIS Exclusion | Frailty Diagnosis | Which Quality Metric | Coding Guidelines and Documentation Best Practice |
|---|--------------------------------|--------------------|----------------------|----------------------------|--|
| Rheumatic heart failure | I09.81 | ** | Yes | | There is no causal relationship to hypertension with this diagnosis. |
| Left ventricular failure, unspecified | I50.1 | ** | Yes | | If a more specific diagnosis is known, do not use this code. |
| Unspecified systolic (congestive) heart failure | 150.20 | ** | Yes | | If the diagnosis used includes preserved ejection fraction, you will need to document the most recent HFpEF in your note. |
| Acute systolic (congestive) heart failure | I50.21 | ** | Yes | | Acute conditions are expected to resolve and should not be added month after month. |
| Chronic systolic (congestive) heart failure | I50.22 | ** | Yes | | |
| Acute on chronic systolic (congestive) heart failure | I50.23 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Unspecified diastolic (congestive) heart failure | 150.30 | ** | Yes | | |
| Acute diastolic (congestive) heart failure | I50.31 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Chronic diastolic (congestive) heart failure | I50.32 | ** | Yes | | |
| Acute on chronic diastolic (congestive) heart failure | I50.33 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Unspecified combined systolic (congestive) and diastolic (congestive) heart failure | I50.40 | ** | Yes | | |
| Acute combined systolic (congestive) and diastolic (congestive) heart failure | I50.41 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Chronic combined systolic (congestive) and diastolic (congestive) heart failure | 150.42 | ** | Yes | | |
| Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure | I50.43 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Right heart failure, unspecified | 150.810 | ** | Yes | | If a more specific diagnosis is known, do not use this code. |

** = The diagnosis is considered a frailty and/or advanced illness diagnosis and may aid in a quality metric exclusion.

| Heart Failure Diagnosis | ICD-10-CM Diagnosis Code | HEDIS Exclusion | | Which Quality Metric | Coding Guidelines and Documentation Best Practice |
|---|--------------------------------|---------------------|-----------------------|----------------------------|--|
| Acute right heart failure | I50.811 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Chronic right heart failure | I50.812 | ** | Yes | | |
| Acute on chronic right heart failure | I50.813 | ** | Yes | | Acute conditions are expected to resolve and should not be recaptured annually. |
| Right heart failure due to left heart failure | I50.814 | ** | Yes | | |
| Biventricular heart failure | 150.82 | ** | Yes | | |
| High output heart failure | 150.83 | ** | Yes | | |
| End stage heart failure | 150.84 | ** | Yes | | |
| Other heart failure | 150.89 | ** | Yes | | If this diagnosis is selected, the "other" type of heart failure must be noted in the documentation. |
| Heart failure, unspecified | I50.9 | ** | Yes | | If a more specific diagnosis is known, do not use this code. |
| Pediatric Heart Failure | ICD-10-CM Diagnosis Code | HEDIS Exclusion? | Frailty Diagnosis? | Which Quality Metric | Coding Guidelines and Documentation Best Practice |
| Neonatal cardiac failure | P29.0 | No | NA | NA | New diagnosis to risk adjustment model in 2024. |
| Hypertensive Heart Disease | ICD-10-CM Diagnosis Code | HEDIS Exclusion? | Frailty Diagnosis? | Which Quality Metric | Coding Guidelines and Documentation Best Practice |
| Hypertensive heart disease with heart failure | I11.0 | Yes | Yes | СВР | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |

** = The diagnosis is considered a frailty and/or advanced illness diagnosis and may aid in a quality metric exclusion.

| Кеу | |
|--|-----|
| Controlling High Blood Pressure | CBP |
| Kidney Health Evaluation for Patients with Diabetes | KED |

| Hypertensive Heart Disease | ICD-10-CM Diagnosis Code | HEDIS Exclusion? | Frailty Diagnosis? | Which Quality Metric | Coding Guidelines and Documentation Best Practice |
|---|--------------------------------|---------------------|-----------------------|----------------------------|--|
| <i>Hypertensive heart disease without heart failure*</i> | I11.9 | Yes | No | СВР | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |
| Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease | I13.0 | Yes | Yes | СВР | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |
| <i>Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease*</i> | I13.10 | Yes | No | СВР | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |
| Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease | I13.11 | Yes | Yes | CBP, KED | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |
| Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease | I13.2 | Yes | Yes | CBP, KED | There is an assumed causal relationship between hypertension and heart failure. Therefore, if the patient's HF is not due to hypertension, you will need to add the cause of the heart failure to your documentation. |

*Note: No HF HCC or RAF, but important to meet CBP quality measure.

| Кеу | |
|--|-----|
| Controlling High Blood Pressure | CBP |
| Kidney Health Evaluation for Patients with Diabetes | KED |

Palliative Care – ICD-10-CM: Z51.5

Quality Metric Exclusions:

- Palliative Care, Pregnancy, Death during the measurement year, ESRD, Dialysis
- Kidney transplant, Nephrectomy, Age 66 0 w/ dx of frailty AND advanced illness, or age \geq 81 two indications of frailty during two different encounters

Direct Test Ordering

Direct Test Ordering

| Direct Test Ordering (No Consult Required) | | | | | | |
|--|--|--|--|---|---|---|
| | BMG | BUMG | Cardiac Solutions | CVAM | Phoenix Heart | Tri-City |
| TIN | 900730397 | 901116753 | 860633950 | 860711625 | 860770482 | 860516994 |
| ECHO | YES | BUMG Patients Only | | YE | S | |
| Exercise Stress Test | YES | BUMG Patients | | YE | S | |
| Nuclear Stress Test | Cardio Consult Required | BUMG Patients Only | | Cardio Consu | It Required | |
| Peripheral Ultrasound | Varies: Contact Amber Scott 602.747.1088 | BUMG Patients Only | | YE | S | |
| Direct Test Notes | Indicate TEST Only , with diagnosing & testing codes | N/A | specify tests | Form: Please s needed and e diagnosis | Indicate TEST Only , with diagnosing & testing codes | TEST Only Form: Please specify tests needed and applicable diagnosis |
| Link to Referral Form | N/A | N/A | <u>Cardiac</u> <u>Solutions</u> <u>Referral Form</u> | <u>CVAM Referral</u> <u>Form</u> | N/A | <u>Tri-City</u> <u>Cardiology</u> <u>Referral Form</u> |
| | | | al Referral De | etails | | |
| Consult Note Return Timeline | A letter will be mail PCP to the address This may be faxed a fax numbe | s on the referral. (e-fax) if there is | 24 | hours | 48-72 hours | 24 hours |
| Backline Numbers | Triage: 480.733.7305 Urgent: 602.747.1088 (Amber Scott, Sr. Mgr.) <u>Referrals:</u> Chandler: 480.733.7306 Baywood: 480.896.3372 | Member Experience Call Center: 602.521.3090 | Priority Referring Physician Direct Line: 623.977.3594 (new & existing patients) | Main Line: 408.641.5400 PCP to Cardiologist: 602.620.7761 CHF Line: 480.654.7112 | Dr. Patel: 602.418.6408 Dr. Sellberg: 602.430.9266 Dr. Gomes: 602.684.1110 Dr. O Khan: 602.684.1125 Dr. Parasher: 602.421.3838 Dr. Dizon: 602.469.7330 Dr. Doss: 480.227.8383 Dr. Kaplan: 602.228.0600 | Priority Referring Physician Direct Line: 480.993.1089 |
| Procedures at Banner Facilities | Ye | 5 | | with Banner Atlas | Yes: Banner Thunderbird Surgery Centers: Atlas Scottsdale | Yes: All East Valley Banner Hospitals |
| Additional Notes | Send all records with referrals & ECG tracing visual documentation | Send medical records, including testing with referral | Abnormal EKG = cardiologist needs the record, please send with referral | Same Day NP & Follow-Up Visits. Notes send automatically via EMR within 24- 72 hours | N/A | Same/Next day appointments for new & established patients |

Disclaimer: A quote of benefits and/or authorization does not guarantee payment or verify eligibility. Payment of benefits are subject to all terms, conditions, limitations, and exclusions of the member's contract at time of service. Please contact the specific health plan for authorization requirements and coverage details.

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Page | 28

Cardiac Solutions



SOLUTIONS PHONE: 623.876.8816 | FAX: 623.933.6739 SCHEDULING@CARDIACSOLUTIONS.NET DIRECT MESSAGE: CARDIACSOLUTIONS@157.DIRECT.EZ.ACCESS.COM PLEASE FAX THE COMPLETED REQUEST FORM TO OUR OFFICE AND WE WILL CONTACT YOUR PATIENT TO SCHEDULE AN APPOINTMENT. FOR URGENT REQUESTS CALL OUR OFFICE. PATIENT INFORMATION NAME: INSURANCE: _____ PHONE: REFERRING PROVIDER: _____ D.O.B : ____ PLEASE INDICATE APPROPRIATE DIAGNOSIS FOR EACH Cardiac Consultation Vascular Consultation New Patient Consult New Patient Consult DIAGNOSIS: DIAGNOSIS: EP Consult DIAGNOSIS: ULTRASOUND TESTING ONLY Abdominal Aorta (must fast 4 hours prior) Echocardiogram DIAGNOSIS: DIAGNOSIS: Ankle Brachial Index (ABI) Pulmonary Function Test (PFT) DIAGNOSIS: DIAGNOSIS: Carotid Doppler Venous Doppler DIAGNOSIS: DIAGNOSIS: Arterial Doppler 🗖 Bilateral 🗖 Left Right DIAGNOSIS: 🗖 Bilateral 🗖 Left 🗖 Right NUCLEAR TESTING ONLY Nuclear Stress Test Regular Treadmill Stress Test DIAGNOSIS: DIAGNOSIS: ____ Chemical Stress Test PATIENT WEIGHT: _____ (required for scheduling) DIAGNOSIS: _ DEL WEBB MEDICAL PLAZA MEDICAL CENTER TALAVI CORPRORATE CENTER WEST 101 GATEWAY 5651 W TALAVI BLVD #160 13460 N. 94TH DR J-1 14420 W. MEEKER BLVD A-305 9520 W PALM LANE #150 PEORIA, AZ 85381 SUN CITY WEST, AZ 85375 GLENDALE, AZ 85306 PHOENIX, AZ 85037 WWW.CARDIACSOLUTIONS.NET | PHONE: 623.876.8816 | FAX: 623.933.6739



New Consult & Testing Order Form

F (480)396-1571 E np@cvam.com

CVAM

| 2 | STAT within 24 h | nours 🗌 Next Avai | ilable |
|--|--|---|--|
| | | 3367 S Mercy Rd, Ste 201, Gilbert, AZ 85297 37200 N Gantzel Rd, Ste 350, Queen Creek, AZ 85140 | |
| Patient Information | | | |
| Name: | | | YY: |
| Phone: Diagnosis (Required): | | Authorization # (| (if required): |
| | | | |
| Requested Physician | | | |
| Alphonse M. Ambrosia, DO Ambrose F. Panico, DO Amy E. Daliman, DO David M. Bell, DO | □ Muhanad Al □ Santosh Des □ Alan M. Gros □ Andrew Will | sai, DO ssman, MD | □ Faraj Kargoli, MD, MPH □ Varun Tandon, MD □ No Preference |
| Consultation | | | |
| New Patient Cardiovascular Consultation Pre-Operative Evaluation Vascular Consultation | | | eart Consultation ology Consultation |
| Testing ONLY | | | |
| Holter Monitor (93241) ABI with Segmentals (93923) Aortic Duplex (93978) Bubble Study (93306) Carotid Ultrasound (93880) Echocardiogram (93306) Lower Extremity Arterial Bilat (93925) Renal Ultrasound (93975 or 93976) Upper Extremity Arterial Ultrasound (93930) Venus Reflux Study (93970) | eral Ultrasound | Pharmacolog Test (78452, A Exercise Stre 93015) Cardiac PET S J2785 x4) ABI with Exer Dobutamine J1250) Exercise Treat | emetry (93228, 93229) gical (Lexiscan) Nuclear Stress A9502X2, J2785X4, & 93015) ss Test (78452, A9502x2, & Scan (78431, A9555 x2, 93015, ecise (93924) Stress Echocardiogram (93351, admill Stress Test (93015) ardiogram (93351) |

Referring Provider Information

| Physician/Provider: | Contact Person: |
|---------------------|----------------------|
| Phone: Fax: | Physician Signature: |

PLEASE ATTACH THE FOLLOWING (Incase authorization from insurance is needed)

□ Patient Demographics □ Copy of Insurance Card □ Blood Work & EKG □ <u>Insurance Referral</u> □ Progress Note □ Written Physician Order/Signed RX (if not sending this form)

Tri-City Cardiology



NEW CONSULT AND TESTING ORDER FORM

PLEASE FAX ALL MEDICAL RECORDS, DEMOGRAPHICS & COPY OF INSURANCE CARDS TO (480) 461-4243. PHYSICIANS AND OFFICE STAFF DIRECT LINE: (480) 993-1089 MULTIPLE CONVENIENT LOCATIONS IN MESA, GILBERT, CHANDLER, SAN TAN VALLEY, CASA GRANDE, AND SUN LAKES INCLUDING STATE-OF-THE-ART VEIN CENTER.

| Cardiology | Interventional Cardiology | Interventional Cardiology & Peripheral Vascular Electrophysiology |
|---------------------|------------------------------|--|
| 1st Available | 1st Available | 1st AvailableDuane Heinrichs, MD* 1st Available |
| Camille Phuc Le, MD | Kelly Guld, MD | Satya Atmakuri, MD*Jaskamal Kahlon, MD* Aron Kolli, MD |
| Loan Nguyen, MD | David Kassel, MD | Joshua Berkowitz, MD*Praneet Sharma, MD* Kai Sung, MD |
| Todd Perlstein, MD | Craig Robison, MD | Sreedivya Chava, MD*Ephraim Weiss, MDBenjamin Jenny, MD |
| Thomas Ritchie, MD | Sulay Patel, MD | Joshua Cohen, MD*Pridhvi Yelamanchili, MD* |
| Arman Talle, MD | Shashank Jain, MD | Rizaldy Villegas, MD*Suntharo Ly, MD* |
| Roger Bies, MD | Jacob Green, MD | Sunny Jhamnani, MD* |
| | | *Performs Venous Ablations |

| ORDERING PHYSICIAN: | |
|-----------------------------|-----------------------|
| OFFICE PHONE #: () - | FAX #:() - |
| PATIENT FIRST NAME: | PATIENT LAST NAME: |
| SOCIAL SECURITY #: | DATE OF BIRTH: |
| PATIENT HOME PHONE #: () - | PATIENT CELL #: () - |
| CARDIOVASCULAR DX: | • |

| | _/F_ |
|--|---|
| Next AvailableWithin 2 weeks | Within 1 weekSTAT |
| Insurance Plan: | ID Number: |
| Office Contact Person: | Direct Phone: |
| Do you require a follow up | with appointment date and time? |
| | call / Yes, fax back / No contact needed Yes (please fax with this form)No |
| Please choose from the following: | (Or) Choose Stress Treadmill Testing: |
| Consultation - please circle (Cardiac / Vascular / | Weight limit for stress testing is 300 lbs. |
| Electrophysiology) | (Patient Weight/Height required for all Treadmill Testing) |
| Echocardiogram (M Mode 2D & Color flow) | Weight: Height: |
| Carotid Duplex Abdominal Ultrasound Holter Monitor (24 hr only) 30 Day Event Monitor Pacemaker/Defibrillator Check Bilateral Venous Ultrasound (Vein Mapping) | Exercise Treadmill Test (ETT) Stress Echocardiogram Nuclear Stress Test/Myocardial Perfusion Imaging Exercise (patient must be able to walk on a treadmill) Pharmacologic Lexiscan Low Level ExerciseNo Exercise Dobutamine |
| EKG Overread | Cardiac PET Imaging |

Care Management and Support Resources

HF Action Plan

Patient Heart Failure (HF) Action Plan



heart.org/HF

© Copyright 2024 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. DS18804 11/24

| O Understand Your HF | Identify Your HF Needs | Are there any activities that are off-limits for me at this time? (List specific concerns you |
|---|--|--|
| How serious is my heart failure? Mild Moderate Severe | Am I a candidate for HF cardiac rehab? Yes No | may have, such as exercise, sex, housewor |
| In what ways does having heart failure increase my health risks? | Are there any additional tests we need to do to learn more about my heart function? If so, which ones? | |
| | | What treatment options should I be thinkin about for managing my HF? |
| How likely is it that having HF will worsen the effects of other conditions I may have? | Explore HF Treatment | |
| | What are the most important things I can do to manage my HF? | What are my treatment goals at this time? |
| Would any of the following lifestyle changes help me to better manage the progress of HF? Managing weight | | • |
| Quitting smoking Making other important changes? | What should I expect in the coming weeks, months or years? | • |
| | | _ ` |
| Symptoms of HF | | ns About Medication |
| Should I be tracking and reporting my symptoms to you? Yes (instructions below) No | Will I be taking a n Yes No | nedication(s) for HF? |
| | What should the n | nedication(s) do? |
| | | |
| What symptoms or problems would you want n | | if I don't take the prescribed medication(s)? |
| | | |
| Learn to recognize and mar | nage symptoms of HF. | |
| | | |
| | | |

HF Action Plan

穿 Banner Health.

Heart Failure Action Plan

| Green Light: Go | Action Plan |
|--|--|
| Breathing: No shortness of breath or trouble breathing at rest or with minimal activity Weight: No weight gain Swelling: No swelling in your feet, ankles, or legs | Plan time every day for walking or other activities, unless your health care provider has given you other instructions Take all medications as directed Continue to weigh yourself every day Eat low-sodium diet If you smoke or chew tobacco, you must quit |

| | Yellow Light: Caution | Action Plan |
|------------|---|---|
| | • Breathing: Shortness of breath at rest, with minimal activity, or while lying flat, and having to sleep with multiple pillows or sitting upright | Call your health care provider if you have any of these symptoms |
| \bigcirc | • Weight: Weight gain of 2-3 pounds in one day, or 5 pounds within a week (whichever amount you were told to report) | |
| | Swelling: Any signs of swelling in feet, ankles, legs or abdomen | |
| | Fatigue: Constant feeling of tiredness | |
| | Decrease in how much you urinate | |



| Red Light: Emergency | Action Plan |
|---|---|
| Breathing: Very short of breath, speaks in single words, struggling to breathe, sitting hunched forward Weight: Weight gain of more than 5 pounds within a week Swelling: Severe swelling in feet, ankles, legs or abdomen Pain: New onset of chest pain New onset of confusion | Call 911 now You need to see a health care provider immediately if you have any of these symptoms |

Reference:

Banner Health Cardiology Clinical Consensus Group (2020)

This information is not intended as a substitute for professional medical care. Always follow your health care provider's instructions.

23-450 9.19.23

Care Management Referral Form

| Completed | Medical Forms can be sent to: |
|---|---|
| Fax: 480-655-2537 or Email: | BHNPopHealthManagement@BannerHealth.com |
| Please send Maternal | Health or Behavioral Health referrals to: |
| Behavioral: BUHPCareMgmtBHMailbox@bannerhealth.c | com Maternal Health: <u>BUHPMaternalChildHealth@bannerhealth.com</u> |
| | oral health concerns shall be initiated through proper emergency or crisis services |
| | rals. Care Management will outreach to the member within 24 business hours. |
| Referral Date: Member Information | Referral Information |
| Primary Health Plan: Please Select | Requested By: |
| Additional Insurances (If Any): | |
| Name | Phone: |
| Address: | |
| ID #: DOB: | |
| Phone:Language: | PCP: |
| Reason(s) fo | or Care Management Request |
| MEDICAL | |
| | nderstanding their diseases, coordinating care with their doctors, etc.) |
| | quent ER visits, frequent PCP changes, medication management issues) |
| Post Discharge Assistance for continued care ma | anagement support |
| Medication Assistance (ex: education, cost barriers) | ;, adherence, and polypharmacy) |
| Chronic condition / Newly diagnosed condition(s) | s) (specify below) |
| Non-adherence to PCP treatment plan, missed a | |
| High Priority Transplant, HIV, Hemophilia memb | er requesting assistance |
| Interdepartmental Medical Management reques | st for immediate assistance |
| | up to 1 year after delivery), Pediatric (under age 21), and CRS |
| Dial Into Diabetes Program – Diabetic Care Mana | agement |
| Home Safety Concerns | |
| Advance Directive / End of Life Planning | |
| Community Resources (ex: financial needs, transpo | ortation, caregiver support, support groups) |
| ALTCS ONLY – Refer to assigned CM / RN | |
| Other (specify below) | |
| BEHAVIORAL | cy for Behavioral Health or indicates need for BH assistance in some |
| way that is not urgent or related to inpatient and/or | |
| | BH services, how to access covered services, complaints, etc. |
| Suicidal / Homicidal caller. (Please refer <u>AFTER</u> you | |
| Member requests referral for BH services (ex: the | |
| Mental Health needs (ex: Dementia, Alzheimer's, dementia) | |
| Urgent need for psychotropic medication | |
| ALTCS ONLY – Refer to assigned CM/RN | |
| Other (specify below) | |
| | Additional Comments (What happened? What do you want done?) |
| | |
| | |
| | |
| | |
| | |

Resources

Palliative Care Providers

| Palliative Care | | | | | | | | | | |
|--|---|------------------------|------------------|-------------------|----------|---------|--------|----------|------------|--------------|
| Provider Name | Webpage | Service Areas | Banner MA HMO | Banner MA DUAL | Aetna MA | BCBS MA | UHC MA | BUHP ACC | BUHP ALTCS | Banner Aetna |
| Doctor Care 480-575-057 7010 E Acoma Dr, Ste 102 Scottsdale, AZ 85254 | https://doctorcareaz.com/about.php_ | Phoenix Metro | x | x | | | | x | x | |
| Casa de la Luz Palliative Care (formerly East Valley Palliative Care) 480-801-2416 2152 S Vineyard, Ste 118 Mesa, AZ 85210 | www.lhcgroup.com | Phoenix Metro | x | x | | | x | x | x | |
| Casa De La Luz Palliative Care 520-544-9890 7740 N Oracle Rd Tucson, AZ 85704 | www.lhcgroup.com | Tucson | x | x | | | | x | x | |
| Sage Primary & Palliative Care 480-771-3400 3030 N Central Ave, Ste 1200 Phoenix, AZ 85012 | www.sagefoc.com | Maricopa, Pinal & Pima | x | x | | | | x | x | × |
| Southwestern Palliative Care 928-276-4477 1950 W 3rd St Yuma, AZ 85364 | www.swpchospice.com | Yuma | x | x | | | | x | x | x |
| Compassus - Phoenix 623-900-2645 5333 N 7th St, STE C-123 Phoenix, AZ 85014 | Compassus Home Health, Infusion, Hospice, & Palliative Care | Maricopa & Pinal | x | x | | | x | x | x | |
| Eternity Hospice & Palliative 602-374-68781 4122 W McDowell Rd, #204 Goodyear, AZ 85395 | www.eternityhospicepalliativecare.com | Phoenix Metro | x | × | | | | x | x | |
| Agave Hospice & Palliative Care 602-855-3500 3240 E. Union Hills Dr, Ste 145 Phoenix, AZ 85050 | <u>Agave – Hospice & Palliative Care</u> (agavehealthcare.com) | Phoenix Metro | x | × | | | x | x | x | |
| Palliative Care Alliance 602-269-6011 426 N 44th St, Ste 450 Phoenix, AZ 85008 | https://palliativeca.com/ | Maricopa & Pinal | | | | | | | × | |
| Divine Hospice & Palliative Care 623-566-7995 18185 N 83rd Ave, Ste 203 Glendale, AZ 85308 | https://www.divinehospiceaz.com/ | Glendale | | × | | | | x | × | |
| Caring Hands Palliative & Hospice Care Inc 602-742-0370 1000 N 31st Ave, D119 Phoenix, AZ 85051 | https://www.caringhandspalhs.com/ | Phoenix Metro | x | x | | | x | x | x | |
| Bristol Palliative Care Services 520-300-9337 5210 E Williams Circle, Ste 530 Tucson, AZ 85711 | https://bristolhospice.com/location/bristol- hospice-tucson/ | Pima | x | x | | | | x | x | |

It has been the objective of Banner to identify local resources available for patients and their families. Any errors or omissions in the above list is unintentional. Furthermore, exclusion from this list does not imply lack of approval, nor does inclusion indicate coverage endorsement of any resource or its program.

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Page | 37

Resources

Home Care Providers

| Home Providers | | | | | | | | | | | |
|--|-----------------------------|------------------------|--------------------------|-------------------|----------|---------|--------|----------|------------|--------------|--|
| Provider Information | Webpage | Service Areas | Banner M A HMO | Banner MA DUAL | Aetna MA | BCBS MA | UHC MA | BUHP ACC | BUHP ALTCS | Banner Aetna | |
| Geriatric Solutions 602-954-0444 1510 E Flower St Phoenix, AZ 85014 | www.geriatricsolutions.org | Maricopa County | x | x | | | x | x | x | | |
| Your Health Connection 480-268-2670 1510 E Flower St Phoenix, AZ 85014 | https://yhcaz.org/_ | Maricopa, Pinal & Pima | x | x | | | x | x | x | | |
| My Doctor Now 480-677-4663 Multiple Locations | www.mydrnow.com | Phoenix Metro | | x | | | x | | | | |
| ASAP Health Solutions 602-996-5595 29455 N Cave Creek Rd #118 Cave Creek, AZ 85331 | www.asaphealthsolutions.com | Phoenix Metro | | x | | | | | | | |
| Southwest Geriatric 520-314-3412 6890 E Sunrise Dr Tucson, AZ 85750 | www.swgeriatrics.com | Tucson | x | x | | | | x | x | | |
| Dispatch Health Urgent Care at Home 480-351-3918 Multiple locations | www.dispatchhealth.com | Phoenix Metro | x | x | | | x | x | x | | |

It has been the objective of Banner to identify local resources available for patients and their families. Any errors or omissions in the above list is unintentional. Furthermore, exclusion from this list does not imply lack of approval, nor does inclusion indicate coverage endorsement of any resource or its program.

Additional Resources

American Heart Association

https://www.heart.org/en/health-topics/heart-failure https://www.heart.org/en/health-topics/heart-failure/heart-failure-tools-resources

Healthier Living with Heart Failure (Interactive workbook)

https://mydigitalpublication.com/publication/?i=753422

References

References

Introduction

 Wong CW, Tafuro J, Azam Z, Satchithananda D, Duckett S, Barker D, Patwala A, Ahmed FZ, Mallen C, Kwok CS. Misdiagnosis of Heart Failure: A Systematic Review of the Literature. J Card Fail. 2021 Sep;27(9):925-933. doi: 10.1016/j.cardfail.2021.05.014. Epub 2021 May 25. PMID: 34048921.

Heart Failure (HF) Provider One Pager

- Abovich A, Matasic DS, Cardoso R, Ndumele CE, Blumenthal RS, Blankstein R, Gulati M. The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention. Am J Prev Cardiol. 2023 Jul 30;15:100527. doi: 10.1016/j.ajpc.2023.100527. PMID: 37637197; PMCID: PMC10457686.
- Dunlay SM, Killian JM, Roger VL, Schulte PJ, Blecker SB, Savitz ST, Redfield MM. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community. J Card Fail. 2022 Oct;28(10):1500-1508. doi: 10.1016/j.cardfail.2022.07.047. Epub 2022 Jul 25. PMID: 35902033; PMCID: PMC9588715.

Care Guidelines: Heart Failure (HF)

- 1. Management of Heart Failure: Updated Guidelines From the AHA/ACC. Ford B, Dore M, Bartlett B. 3, s.l. : AAFP, 2023, Vol. 108.
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. . Heidenreich, P, Bozkurt, B, Aguilar, D. et al. 17, s.l. : J Am Coll Cardiol, 2022, Vol. 79.
- 3. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. Yancy CW, Januzzi JL, Allen LA, et al. 201, s.l. : JACC, 2018, Vol. 71.

Medication Guidelines: Heart Failure (HF)

- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e876-e894. doi:10.1161/CIR.00000000001062
- Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *Eur Heart J*. 2010;31(7):824-831. doi:10.1093/eurheartj/ehp604
- Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. *J Card Fail*. 2008;14(6):445-452. doi:10.1016/j.cardfail.2008.02.007
- Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385-392. doi:10.1056/NEJM198808183190701
- Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. *Circulation*. 1991;83(1):52-60. doi:10.1161/01.cir.83.1.52
- Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). *Am J Cardiol*. 1990;66(10):779-785. doi:10.1016/0002-9149(90)90351-z
- 7. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a

population-based cohort study. *Lancet*. 2004;363(9423):1751-1756. doi:10.1016/S0140-6736(04)16299-5

- 8. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. *Arch Intern Med*. 2009;169(2):141-149. doi:10.1001/archinternmed.2008.525
- 9. Ferreira JP, Mehta C, Sharma A, Nissen SE, Rossignol P, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. *BMC Med*. 2020;18(1):165. Published 2020 Jun 4. doi:10.1186/s12916-020-01616-8

Resources for Coding

- CMS 2024 ICD-10-CM Coding Manual
- Optum 2024 ICD-10-CM Expert for Physicians
- 3M Coding reference- Integrated Codebook
- Stage B heart failure: <u>https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure</u>>

Acronyms

| ACEi: | Angiotensin converting enzyme inhibitor |
|-----------|--|
| ARB: | Angiotensin receptor blocker |
| ARNi: | Angiotensin receptor-neprilysin inhibitor |
| AWV: | Annual Wellness Visit |
| BHC: | Banner Home Care |
| BHN: | Banner Health Network |
| BID: | Twice a day |
| BP: | Blood pressure |
| BUN: | Blood urea nitrogen |
| CAD: | Coronary artery disease |
| CHF: | Congestive heart failure |
| CKD: | Chronic kidney disease |
| CR: | Controlled release |
| CRT: | Cardiac resynchronization therapy |
| DDP-4: | Dipeptidyl peptidase 4 inhibitor |
| ED: | Emergency Department |
| EF: | Ejection fraction |
| GDMT: | Guideline-directed medical therapy |
| GLP-1 RA: | Glucagon-like peptide 1 receptor agonists |
| HF: | Heart Failure |
| HFimpEF: | Heart failure with improved ejection fraction |
| HFmrEF: | Heart failure with midrange ejection fraction |
| HFpEF: | Heart failure with preserved ejection fraction |
| HFrEF: | Heart failure with reduced ejection fraction |
| HTN: | Hypertension |
| ICD: | Implantable cardioverter defibrillator |
| LVEF: | Left ventricular ejection fraction |
| mg/dL: | Milligrams per deciliter |
| MI: | Myocardial infarction |
| mmHg: | Millimeters of mercury |
| MRA: | Mineralocorticoid receptor antagonist |
| NSAIDs: | Non-steroidal anti-inflammatory drugs |
| NYHA: | New York Heart Association |
| PCP: | Primary Care Physician |
| PHS: | Population Health Services Organization |
| Qday: | Once a day |
| RD: | Registered Dietitian |
| RN: | Registered Nurse |
| SDOH: | Social Determinants of Health |
| SGLT-2i: | Sodium-glucose cotransporter-2 inhibitors |
| SUD: | Substance Use Disorder |
| SW: | Social Worker |
| TID: | Three times a day |
| XL: | Extended release |
| /\L. | |